Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JGPMA Accepted as Full Member of IGPA
December 10, 2007
- Another Reduction in Medical Fees Non Recommendable: Chuikyo
December 10, 2007
- Kobashou's Shareholders Approve Share Exchange with Mediceo
December 10, 2007
- ZERIA: Ethical Drugs Down, Consumer Healthcare Products Up
December 3, 2007
- OPINION／Why Japanese Executives Are Grossly Underpaid
December 3, 2007
- Fuso: First Operating, Ordinary Losses Since Listing
December 3, 2007
- TOPICS／CareNet, Recruit Start Career Support Services for Doctors
December 3, 2007
- Wakamoto: Rysmon TG Shows Strong Growth
December 3, 2007
- MEDICAL DEVICE NEWS IN BRIEF
December 3, 2007
- CMIC: Addition of CMIC SS CMO Boosts Sales, Profits
December 3, 2007
- GENERICS NEWS IN BRIEF
December 3, 2007
- EPS: CRO, SMO Businesses Drives Sales, Profits
December 3, 2007
- Gov't Appeals Asserting Legitimacy of Kongo Shinryo
December 3, 2007
- Diovan Remains No.1 for 6th Month in a Row: Rep Track Survey
December 3, 2007
- Kyowa Hakko and Kirin Pharma Are a Perfect Match: Dr Matsuda
December 3, 2007
- Wider Range of Drugs to Be Re-Priced in Next Price Revision
December 3, 2007
- Re-Pricing of ARBs May Be Necessary: Mr Niwa
December 3, 2007
- Council Calls For "Extraordinary NHI Drug Price Cuts"
December 3, 2007
- Re-Pricing Runs Counter to the Promotion of Innovation: Dr Aoki
December 3, 2007
- REGULATORY NEWS IN BRIEF
December 3, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…